the product in the database has an inactive status
indications:
Treatment of peptic ulcer of the stomach and duodenum; treatment of ulcers occurring after stomach operations; prevention of recurrent ulceration of the stomach and duodenum; relieving the symptoms of gastro-oesophageal reflux; Zollinger-Ellison syndrome; prevention of Mendelson syndrome (before general anesthesia in women who have a risk of aspiration of hydrochloric acid).
Composition:
1 tabl powl. contains 150 mg of Ranitidine as hydrochloride.
Action:
Competitive antagonist of the histamine H receptor2 in the stomach mucosa. It inhibits the secretion of hydrochloric acid, both basic and stimulated by food. It also reduces the secretion of pepsin. After oral administration, it is well absorbed from the gastrointestinal tract. After 2 hours, it reaches its maximum concentration in the blood. It works about 12 hours. It is excreted in the urine, mainly in unchanged form. It passes through the placenta barrier and into breast milk.
Contraindications:
Hypersensitivity to ranitidine or other ingredients of the preparation. acute porphyria in the interview. The drug should not be used in children under 15 years of age.
Precautions:
Use with caution in liver and kidney disorders.
Pregnancy and lactation:
During pregnancy, use only if definitely necessary and only for a short time. Use during breastfeeding is not recommended.
Side effects:
They occurred in 3-7% of patients and included: pain and dizziness, nausea, dry mouth, bloating, constipation, diarrhea, decreased appetite. Confusion, depression and hallucinations have been rare (especially in the elderly). Menstrual disorders and alopecia were rare. It is possible to increase the activity of liver enzymes and urea in the blood. Leukopenia, thrombocytopenia and sporadic hepatitis (cellular, cholestatic and mixed) with or without icterus have been observed. Acute pancreatitis occasionally occurred. Rare cases of agranulocytosis or aplastic anemia have been observed, sometimes associated with hypoplasia or bone marrow aplasia. There have also been cases of hypersensitivity reactions (urticaria, angioneurotic edema, fever, bronchospasm, hypotension, anaphylactic shock, chest pains). Occasionally, bradycardia, atrio-ventricular block and cardiac arrest occurred. During the use of Ranitidine, transient renal dysfunction was sometimes observed. In rare cases, joint and muscle pain were observed, and in some cases mastopathy.
Dosage:
Orally. Treatment of peptic ulcer of the stomach and duodenum; treatment of ulcers occurring after stomach operations: adults usually 150 mg twice daily (morning and evening) or 300 mg in the evening for 4 weeks, if necessary, the drug can be administered for another 4 weeks. Prevention of recurrent stomach and duodenum ulcer: 150 mg once daily before bedtime. Relief of symptoms of gastro-oesophageal reflux: 150 mg 2 times a day for 2 weeks, if symptoms persist - the drug can be extended up to 4 weeks. Zollinger-Ellison syndrome: initially 150 mg 3 times a day, if necessary the dose can be increased (doses up to 6 g per day were well tolerated). Prevention of Mendelson syndrome (before general anesthesia in women who have a risk of aspiration of hydrochloric acid): 150 mg every 6 hours. In renal failure, ranitidine should be used depending on the creatinine clearance: at a clearance below 50 ml / min, the daily dose should be reduced to 150 mg; dialysis patients Ranitidine should be administered after dialysis.